<DOC>
	<DOC>NCT00655200</DOC>
	<brief_summary>This study is conducted in Asia. The aim of this observational study is to evaluate the safety and tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the treatment of Filipino patients with Type 1 and Type 2 Diabetes Mellitus.</brief_summary>
	<brief_title>Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Patients diagnosed with Type 1 or Type 2 Diabetes Mellitus. Newly diagnosed insulin naive patients Patients currently on human insulin or on basal insulin Patients prescribed with Levemir™ FlexPen™ (Insulin Detemir) therapy Usage should be in accordance with the current prescribing information (See attached prescribing information) Previous history of hypersensitivity to Insulin Detemir (Levemir™) and its excipients (See attached prescribing information) Contraindications and warnings specified in the current prescribing information (See attached prescribing information) Pregnant women, those planning to become pregnant, or women who are breastfeeding Patients who are already on human premix or premix analogue (unless they are going to be shifted to basalbolus therapy) Children below 6 years old</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>